(Q36455879)

14 August 2017

title

Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease (English)

1 reference

14 August 2017

Faergeman O

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Journal of Internal Medicine

14 August 2017

published in

1 reference

14 August 2017

volume

259

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

434-436

1 reference

Coronary Calcification, Coronary Disease Risk Factors, C-Reactive Protein, and Atherosclerotic Cardiovascular Disease Events

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Coronary plaque as a replacement for age as a risk factor in global risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Efficacy of lipid profiles in prediction of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

The rationale for using apoA-I as a clinical marker of cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Apolipoproteins AI and B as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Cardioprotective effects of high-density lipoproteins: the evidence strengthens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is...

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01650.X

10.1111/J.1365-2796.2006.01650.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference